Disease activity after natalizumab discontinuation in multiple sclerosis: reactivation or rebound?

被引：0
|
作者：
Borriello, G. [1 ]
Prosperini, L. [1 ]
Mancinelli, C. [1 ]
Fubelli, F. [1 ]
Gianni, C. [1 ]
Marinelli, F. [1 ]
Pozzilli, C. [1 ]
机构：
[1] S Andrea Hosp, Rome, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P529
引用
收藏
页码：S228 / S228
页数：1
相关论文
共 50 条
  • [41] Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
    Joachim Havla
    Björn Tackenberg
    Kerstin Hellwig
    Ingrid Meinl
    Markus Krumbholz
    Florian Seitz
    Christian Eienbröker
    Ralf Gold
    Reinhard Hohlfeld
    Ingo Kleiter
    Tania Kümpfel
    Journal of Neurology, 2013, 260 : 1382 - 1387
  • [42] Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis
    O'Connor, P. W.
    Goodman, A. D.
    Kappos, L.
    Lublin, F. D.
    Miller, D. H.
    Polman, C. H.
    Rudick, R. A.
    Forrestal, F.
    Jurgensen, S.
    Panzara, M. A.
    Sandrock, A. W.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S240 - S241
  • [43] What to expect one year after natalizumab discontinuation in multiple sclerosis patients
    Sangalli, F.
    Moiola, L.
    Ferre, L.
    Radaelli, M.
    Barcella, V.
    Martinelli, V.
    Comi, G.
    JOURNAL OF NEUROLOGY, 2012, 259 : S108 - S108
  • [44] IRIS in a Multiple Sclerosis Patient after Discontinuation of Natalizumab and Newly Started on Fingolimod
    Tomas, Erica
    Wall, Anastacia
    Malik, Amer
    Jung-Henson, Lily
    NEUROLOGY, 2012, 78
  • [45] Rebound of disease activity after discontinuation of natalizumab or fingolimod can be successfully treated with autologous haematopoietic stem cell transplantation
    Curro, D.
    Gualandi, F.
    Cavalla, P.
    Capello, E.
    Uccelli, A.
    Mattioda, A.
    Boffa, G.
    Mancardi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 621 - 622
  • [46] Can ocrelizumab prevent MS reactivation after discontinuation of natalizumab?
    Repovic, P.
    Smoot, K.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 508 - 508
  • [47] Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy
    Sormani, Maria Pia
    De Stefano, Nicola
    NEUROLOGY, 2014, 82 (17) : 1484 - 1485
  • [48] No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation
    Capobianco, M.
    di Sapio, A.
    Malentacchi, M.
    Malucchi, S.
    Matta, M.
    Sperli, F.
    Bertolotto, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (03) : 585 - 587
  • [49] Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports
    Fuerte-Hortigon, A.
    Ruiz, R. Lopez
    Hiraldo, J. D. G.
    Fernandez, F. Sanchez
    Garcia-Soto, J. Dotor
    Paramo, Maria Dolores
    Ruiz-Pena, J. L.
    Navarro-Mascarell, G.
    Eichau, S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
  • [50] Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau, J.
    Sormani, M. P.
    Signori, A.
    Realmuto, S.
    Baroncini, D.
    Annovazzi, P.
    Signoriello, E.
    Maniscalco, G. T.
    La Gioia, S.
    Cordioli, C.
    Frigeni, B.
    Rasia, S.
    Fenu, G.
    Grasso, R.
    Sartori, A.
    Lanzillo, R.
    Cocco, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 911 - 912
12345